Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Summit Therapeutics Inc (SMMT) Price & Performance

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETFTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Summit Therapeutics Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

FLRNSMMT
Sector
Sector/ThematicHealth
52-Week High
$30.86$26.98
52-Week Low
$30.65$12.55
Market Cap
$12.06B
Enterprise Value
$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure, though RSI near 20 indicates potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share throughout 2026, providing income stability for shareholders despite the challenging technical backdrop.

The stock faces headwinds from bearish technical momentum while offering dividend stability. Investment opportunity exists for income-focused investors attracted to the consistent dividend yield, though technical weakness suggests near-term price pressure. Key risks include broader market volatility and the stock's inability to break through resistance levels amid current bearish sentiment.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.

Read more on FLRN

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT